<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01266161</url>
  </required_header>
  <id_info>
    <org_study_id>B3491001</org_study_id>
    <secondary_id>AK-10-13</secondary_id>
    <nct_id>NCT01266161</nct_id>
  </id_info>
  <brief_title>Multiple Dose Dental Pain Study Of Ibuprofen Extended Release</brief_title>
  <official_title>A Multiple Dose Dental Pain Study Of An Ibuprofen 600 Mg Extended Release Caplet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypothesis is that single and multiple doses of ibuprofen 600 mg ER caplets provide
      analgesic efficacy superior to placebo over 12-hour dosing intervals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 22, 2010</start_date>
  <completion_date type="Actual">March 31, 2011</completion_date>
  <primary_completion_date type="Actual">March 31, 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-weighted Sum of Pain Relief and Pain Intensity Difference Scores From 0 to 12 Hours After the First Dose (SPRID 0-12)</measure>
    <time_frame>Baseline to 12 hours</time_frame>
    <description>SPRID is time-weighted sum of pain relief (PR) plus pain intensity (PI) difference (PID) (PRID) scores. 5-point categorical scale for PR: &quot;How much relief do you have from your starting pain?&quot; (0 equals [=] none, 1=a little, 2=some, 3=a lot, 4=complete). 4-point categorical scale for PI: &quot;How much pain do you have at this time?&quot; (0=none, 1=mild, 2=moderate, 3=severe). PID score=baseline pain intensity score minus pain intensity at each time point; score ranged from -1 to 3; higher positive PID value indicated improvement in pain intensity. SPRID 0-12 score ranged from -12 to 84; higher score indicated better efficacy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sum of Pain Relief and Pain Intensity Difference Scores From 8-12 Hours After the First Dose</measure>
    <time_frame>8 to 12 hours</time_frame>
    <description>SPRID is time-weighted sum of PR plus PID (PRID) scores. 5-point categorical scale for PR: &quot;How much relief do you have from your starting pain?&quot; (0=none, 1=a little, 2=some, 3=a lot, 4=complete). 4-point categorical scale for pain intensity: &quot;How much pain do you have at this time?&quot; (0=none, 1=mild, 2=moderate, 3=severe). PID score=baseline pain intensity score minus pain intensity at each time point; score ranged from -1 to 3; higher positive PID value indicated improvement (decrease) in pain intensity. SPRID 8-12 score ranged from -4 to 28; higher score indicated better efficacy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time-weighted Sum of Pain Intensity Difference (SPID) Scores</measure>
    <time_frame>0 to 12 hours, 8 to 12 hours, 12 to 24 hours, 20 to 24 hours, 0 to 24 hours, 24 to 36 hours, 32 to 36 hours, 36 to 48 hours, 44 to 48 hours, 24 to 48 hours</time_frame>
    <description>SPID is a derived endpoint from PID scores. For pain intensity, &quot;How much pain do you have at this time?&quot; answered on a 4-point categorical scale (0=none, 1=mild, 2=moderate, 3=severe). PID score=baseline pain intensity score minus pain intensity at each time point; score ranged from -1 to 3; higher positive PID value indicated improvement (decrease) in pain intensity. SPID scores ranged as follows: 0 to 12 hour (-11.5 to 35.5), 8 to 12 hour (-6.0 to 18.0), 12 to 24 hour (-14.0 to 42.0), 20 to 24 hour (-8.0 to 24.0), 0 to 24 hour (-23.5 to 71.5), 24 to 36 hour (-16.0 to 48.0), 32 to 36 hour (-8.0 to 24.0), 36 to 48 hour (-16.0 to 48.0), 44 to 48 hour (-8.0 to 24.0), 24 to 48 hour (-28.0 to 84.0); higher positive values indicated improvement (decrease) in pain intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Dose of Rescue Medication After First Dose of Study Drug</measure>
    <time_frame>Baseline to 12 hours</time_frame>
    <description>During the first 12 hours of the study, participants not experiencing adequate relief after the 1-hour time point were allowed to take a single tablet (dose) of acetaminophen/hydrocodone hydrochloride (HCl) 500 mg/5 mg as a rescue medication (the only rescue medication allowed). The time at which rescue medication was taken was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Taking Rescue Medication</measure>
    <time_frame>Baseline to 48 hours</time_frame>
    <description>Participants not experiencing adequate relief after the 1-hour time point during each dosing interval were allowed to take a single tablet (dose) of acetaminophen/hydrocodone HCl 500 mg/5 mg as a rescue medication (the only rescue medication allowed) during each interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief (PR) Scores</measure>
    <time_frame>0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 hours</time_frame>
    <description>A 5-point categorical pain relief rating scale was used to rate pain relief in response to the question: &quot;How much relief do you have from your starting pain?&quot; Responses were scored as follows: 0=none, 1=a little, 2=some, 3=a lot, 4=complete. Higher score indicated more pain relief.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Intensity Difference (PID) Scores</measure>
    <time_frame>0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 hours</time_frame>
    <description>For pain intensity, &quot;How much pain do you have at this time?&quot; answered on a 4-point categorical scale. Responses were scored as follows: 0=none, 1=mild, 2=moderate, 3=severe. PID score=baseline pain intensity score minus score at each time point. PID scores ranged from -1 to 3. Higher positive PID scores indicated greater improvement (decrease in pain intensity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Relief Combined With Pain Intensity (PRID) Scores</measure>
    <time_frame>0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 hours</time_frame>
    <description>PRID score=PR plus PID. 5-point categorical scale for PR: &quot;How much relief do you have from your starting pain?&quot; (0=none, 1=a little, 2=some, 3=a lot, 4=complete). 4-point categorical scale for pain intensity: &quot;How much pain do you have at this time?&quot; (0=none, 1=mild, 2=moderate, 3=severe). PID score=baseline pain intensity score minus pain intensity at each time point; PID score ranged from -1 to 3; higher positive PID value=improvement. PRID scores ranged from -1 to 7. Higher PRID scores indicated better pain relief and decrease in pain intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-weighted Sum of Pain Relief Scores (TOTPAR)</measure>
    <time_frame>0-12 hours, 8-12 hours</time_frame>
    <description>TOTPAR is a derived endpoint from PR scores. 5-point categorical scale for PR: &quot;How much relief do you have from your starting pain?&quot; (0=none, 1=a little, 2=some, 3=a lot, 4=complete). TOTPAR 0-12 scores ranged from 0 (worst) to 48 (best). TOTPAR 8-12 scores ranged from 0 (worst) to 16 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Doses of Rescue Medication Used</measure>
    <time_frame>0-12, 12-24, 24-36, 36-48, 0-48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Confirmed First Perceptible Relief</measure>
    <time_frame>Baseline to 12 hours</time_frame>
    <description>The elapsed time from dosing until the participant indicated first perceptible pain relief by pressing the first stopwatch, provided the participant also indicated achieving meaningful relief by pressing the second stopwatch. Perceptible relief defined as when participant first began to feel any pain-relieving effect whatsoever of the drug. Did not necessarily mean the participant felt completely better, but when the participant first felt any difference in the pain he/she is currently feeling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Meaningful Relief</measure>
    <time_frame>Baseline to 12 hours</time_frame>
    <description>Participants evaluated the time to meaningful relief by depressing a second stopwatch at the moment they first began to experience meaningful relief, defined as relief from the pain that was considered meaningful to the participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Global Evaluation Score</measure>
    <time_frame>24 and 48 hours</time_frame>
    <description>Participants responded, on a 6-point categorical scale, to the following question: &quot;How would you rate this medication as a pain-reliever?&quot; Responses on this categorical scale ranged as follows: 0=very poor, 1=poor, 2=fair, 3=good, 4=very good, 5=excellent.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">106</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Ibuprofen 600 mg extended release</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen 600 mg ER</intervention_name>
    <description>One 600 mg caplet dosed at 0, 12, 24 and 36 hours</description>
    <arm_group_label>Ibuprofen 600 mg extended release</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One placebo caplet dosed at times 0, 12, 24 and 36 hours</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females 16 to 40 years of age

          -  Subjects who undergo surgical removal of at least two third molars

          -  One of which must be a partial or full bony mandibular impaction

          -  Subjects must have at least moderate baseline pain (a score of 2 on the categorical
             pain severity rating scale) confirmed by a score of at least 50 mm on the 100-mm
             visual analog scale-pain severity rating scale (VAS-PSR)

        Exclusion Criteria:

          -  Acute localized dental infection at the time of surgery that could confound the
             post-surgical evaluation

          -  Presence or history of any significant organ disease

          -  Use of prescription or OTC first generation antihistamines

          -  Females who are pregnant, lactating or of childbearing potential and not using a
             medically approved method to prevent pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Texas Oral Surgery Associates</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3491001&amp;StudyName=Multiple%20Dose%20Dental%20Pain%20Study%20Of%20Ibuprofen%20Extended%20Release</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>December 22, 2010</study_first_submitted>
  <study_first_submitted_qc>December 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2010</study_first_posted>
  <results_first_submitted>February 20, 2013</results_first_submitted>
  <results_first_submitted_qc>August 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 15, 2018</results_first_posted>
  <disposition_first_submitted>April 19, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>April 19, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 24, 2012</disposition_first_posted>
  <last_update_submitted>August 13, 2018</last_update_submitted>
  <last_update_submitted_qc>August 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dental pain</keyword>
  <keyword>multiple dose</keyword>
  <keyword>ibuprofen</keyword>
  <keyword>third molar extraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Toothache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo 1 matching caplet administered orally up to 5 hours after surgery, thereafter every 12 hours up to 48 hours</description>
        </group>
        <group group_id="P2">
          <title>Ibuprofen</title>
          <description>Ibuprofen 600 milligrams (mg) extended release (ER) caplet administered orally up to 5 hours after surgery, thereafter every 12 hours up to 48 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Ineligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Vomited within 4 hours of dosing</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo 1 matching caplet administered orally up to 5 hours after surgery, thereafter every 12 hours up to 48 hours</description>
        </group>
        <group group_id="B2">
          <title>Ibuprofen</title>
          <description>Ibuprofen 600 milligrams (mg) extended release (ER) caplet administered orally up to 5 hours after surgery, thereafter every 12 hours up to 48 hours</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
            <count group_id="B2" value="54"/>
            <count group_id="B3" value="106"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.1" spread="3.3"/>
                    <measurement group_id="B2" value="21.3" spread="3.6"/>
                    <measurement group_id="B3" value="21.2" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain Severity</title>
          <description>A 4-point categorical pain severity rating scale was used to rate the severity of baseline pain in response to the query &quot; My starting pain is:&quot; Responses ranged and were scored as follows: None (0), Mild (1), Moderate (2), Severe (3). A baseline pain intensity score of at least moderate was required for study enrollment.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pain Intensity</title>
          <description>A 100-millimeter (mm) visual analog scale-pain severity rating (VAS-PSR) rated intensity of baseline pain. Participants were asked to &quot;Draw a single vertical line on the scale that shows how much pain you have at this time.&quot; Scores on this 100-mm linear scale measured to nearest millimeter from left. Zero on the scale represented no pain and 100 represented the worst pain. Score of at least 50 mm required for enrolment.</description>
          <units>millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.8" spread="12.25"/>
                    <measurement group_id="B2" value="75.7" spread="12.18"/>
                    <measurement group_id="B3" value="74.8" spread="12.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time-weighted Sum of Pain Relief and Pain Intensity Difference Scores From 0 to 12 Hours After the First Dose (SPRID 0-12)</title>
        <description>SPRID is time-weighted sum of pain relief (PR) plus pain intensity (PI) difference (PID) (PRID) scores. 5-point categorical scale for PR: &quot;How much relief do you have from your starting pain?&quot; (0 equals [=] none, 1=a little, 2=some, 3=a lot, 4=complete). 4-point categorical scale for PI: &quot;How much pain do you have at this time?&quot; (0=none, 1=mild, 2=moderate, 3=severe). PID score=baseline pain intensity score minus pain intensity at each time point; score ranged from -1 to 3; higher positive PID value indicated improvement in pain intensity. SPRID 0-12 score ranged from -12 to 84; higher score indicated better efficacy.</description>
        <time_frame>Baseline to 12 hours</time_frame>
        <population>Intent-to-treat (ITT) population: Randomized participants with at least moderate baseline pain (score 2 on the pain severity rating [PSR] scale) confirmed by a score of at least 50 millimeter (mm) on the 100-mm visual analog scale (VAS)-PSR, within approximately 5 hours after surgery, provided a baseline assessment, and received study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo 1 matching caplet administered orally up to 5 hours after surgery, thereafter every 12 hours up to 48 hours</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen</title>
            <description>Ibuprofen 600 milligrams (mg) extended release (ER) caplet administered orally up to 5 hours after surgery, thereafter every 12 hours up to 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Time-weighted Sum of Pain Relief and Pain Intensity Difference Scores From 0 to 12 Hours After the First Dose (SPRID 0-12)</title>
          <description>SPRID is time-weighted sum of pain relief (PR) plus pain intensity (PI) difference (PID) (PRID) scores. 5-point categorical scale for PR: &quot;How much relief do you have from your starting pain?&quot; (0 equals [=] none, 1=a little, 2=some, 3=a lot, 4=complete). 4-point categorical scale for PI: &quot;How much pain do you have at this time?&quot; (0=none, 1=mild, 2=moderate, 3=severe). PID score=baseline pain intensity score minus pain intensity at each time point; score ranged from -1 to 3; higher positive PID value indicated improvement in pain intensity. SPRID 0-12 score ranged from -12 to 84; higher score indicated better efficacy.</description>
          <population>Intent-to-treat (ITT) population: Randomized participants with at least moderate baseline pain (score 2 on the pain severity rating [PSR] scale) confirmed by a score of at least 50 millimeter (mm) on the 100-mm visual analog scale (VAS)-PSR, within approximately 5 hours after surgery, provided a baseline assessment, and received study medication.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.2" spread="20.0"/>
                    <measurement group_id="O2" value="41.5" spread="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Value from analysis of variance (ANOVA) model, with treatment, baseline PSR, gender terms. To protect type I error at 5% significance, 2 primary parameters tested sequentially: SPRID 8-12 not declared significant unless SPRID 0-12 was significant.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>23.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>16.45</ci_lower_limit>
            <ci_upper_limit>31.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sum of Pain Relief and Pain Intensity Difference Scores From 8-12 Hours After the First Dose</title>
        <description>SPRID is time-weighted sum of PR plus PID (PRID) scores. 5-point categorical scale for PR: &quot;How much relief do you have from your starting pain?&quot; (0=none, 1=a little, 2=some, 3=a lot, 4=complete). 4-point categorical scale for pain intensity: &quot;How much pain do you have at this time?&quot; (0=none, 1=mild, 2=moderate, 3=severe). PID score=baseline pain intensity score minus pain intensity at each time point; score ranged from -1 to 3; higher positive PID value indicated improvement (decrease) in pain intensity. SPRID 8-12 score ranged from -4 to 28; higher score indicated better efficacy.</description>
        <time_frame>8 to 12 hours</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo 1 matching caplet administered orally up to 5 hours after surgery, thereafter every 12 hours up to 48 hours</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen</title>
            <description>Ibuprofen 600 milligrams (mg) extended release (ER) caplet administered orally up to 5 hours after surgery, thereafter every 12 hours up to 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Sum of Pain Relief and Pain Intensity Difference Scores From 8-12 Hours After the First Dose</title>
          <description>SPRID is time-weighted sum of PR plus PID (PRID) scores. 5-point categorical scale for PR: &quot;How much relief do you have from your starting pain?&quot; (0=none, 1=a little, 2=some, 3=a lot, 4=complete). 4-point categorical scale for pain intensity: &quot;How much pain do you have at this time?&quot; (0=none, 1=mild, 2=moderate, 3=severe). PID score=baseline pain intensity score minus pain intensity at each time point; score ranged from -1 to 3; higher positive PID value indicated improvement (decrease) in pain intensity. SPRID 8-12 score ranged from -4 to 28; higher score indicated better efficacy.</description>
          <population>ITT population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="12.0"/>
                    <measurement group_id="O2" value="18.4" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Value from ANOVA model, with treatment, baseline PSR, and gender terms. To protect type I error at 5% significance, 2 primary parameters tested sequentially: SPRID 8-12 not declared significant unless SPRID 0-12 was significant.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>8.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.13</ci_lower_limit>
            <ci_upper_limit>12.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-weighted Sum of Pain Intensity Difference (SPID) Scores</title>
        <description>SPID is a derived endpoint from PID scores. For pain intensity, &quot;How much pain do you have at this time?&quot; answered on a 4-point categorical scale (0=none, 1=mild, 2=moderate, 3=severe). PID score=baseline pain intensity score minus pain intensity at each time point; score ranged from -1 to 3; higher positive PID value indicated improvement (decrease) in pain intensity. SPID scores ranged as follows: 0 to 12 hour (-11.5 to 35.5), 8 to 12 hour (-6.0 to 18.0), 12 to 24 hour (-14.0 to 42.0), 20 to 24 hour (-8.0 to 24.0), 0 to 24 hour (-23.5 to 71.5), 24 to 36 hour (-16.0 to 48.0), 32 to 36 hour (-8.0 to 24.0), 36 to 48 hour (-16.0 to 48.0), 44 to 48 hour (-8.0 to 24.0), 24 to 48 hour (-28.0 to 84.0); higher positive values indicated improvement (decrease) in pain intensity.</description>
        <time_frame>0 to 12 hours, 8 to 12 hours, 12 to 24 hours, 20 to 24 hours, 0 to 24 hours, 24 to 36 hours, 32 to 36 hours, 36 to 48 hours, 44 to 48 hours, 24 to 48 hours</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo 1 matching caplet administered orally up to 5 hours after surgery, thereafter every 12 hours up to 48 hours</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen</title>
            <description>Ibuprofen 600 milligrams (mg) extended release (ER) caplet administered orally up to 5 hours after surgery, thereafter every 12 hours up to 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Time-weighted Sum of Pain Intensity Difference (SPID) Scores</title>
          <description>SPID is a derived endpoint from PID scores. For pain intensity, &quot;How much pain do you have at this time?&quot; answered on a 4-point categorical scale (0=none, 1=mild, 2=moderate, 3=severe). PID score=baseline pain intensity score minus pain intensity at each time point; score ranged from -1 to 3; higher positive PID value indicated improvement (decrease) in pain intensity. SPID scores ranged as follows: 0 to 12 hour (-11.5 to 35.5), 8 to 12 hour (-6.0 to 18.0), 12 to 24 hour (-14.0 to 42.0), 20 to 24 hour (-8.0 to 24.0), 0 to 24 hour (-23.5 to 71.5), 24 to 36 hour (-16.0 to 48.0), 32 to 36 hour (-8.0 to 24.0), 36 to 48 hour (-16.0 to 48.0), 44 to 48 hour (-8.0 to 24.0), 24 to 48 hour (-28.0 to 84.0); higher positive values indicated improvement (decrease) in pain intensity.</description>
          <population>ITT population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SPID 0-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="9.6"/>
                    <measurement group_id="O2" value="12.8" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPID 8-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="5.4"/>
                    <measurement group_id="O2" value="5.5" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPID 12-24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="12.5"/>
                    <measurement group_id="O2" value="18.7" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPID 20-24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8" spread="7.5"/>
                    <measurement group_id="O2" value="10.7" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPID 0-24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" spread="19.3"/>
                    <measurement group_id="O2" value="29.9" spread="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPID 24-36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" spread="15.2"/>
                    <measurement group_id="O2" value="21.6" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPID 32-36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0" spread="7.8"/>
                    <measurement group_id="O2" value="10.2" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPID 36-48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" spread="14.2"/>
                    <measurement group_id="O2" value="23.0" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPID 44-48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5" spread="7.7"/>
                    <measurement group_id="O2" value="12.7" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPID 24-48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.5" spread="25.2"/>
                    <measurement group_id="O2" value="40.7" spread="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For SPID 0-12.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Value from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least-squares means</param_type>
            <param_value>8.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.94</ci_lower_limit>
            <ci_upper_limit>11.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For SPID 8-12.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Value from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least-squares means</param_type>
            <param_value>3.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.45</ci_lower_limit>
            <ci_upper_limit>4.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For SPID 12-24.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Value from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least-squares means</param_type>
            <param_value>6.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.84</ci_lower_limit>
            <ci_upper_limit>10.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For SPID 20-24.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.091</p_value>
            <p_value_desc>p-Value from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least-squares means</param_type>
            <param_value>2.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.33</ci_lower_limit>
            <ci_upper_limit>4.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For SPID 0-24.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Value from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least-squares means</param_type>
            <param_value>14.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.12</ci_lower_limit>
            <ci_upper_limit>20.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For SPID 24-36.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.010</p_value>
            <p_value_desc>p-Value from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least-squares means</param_type>
            <param_value>5.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.42</ci_lower_limit>
            <ci_upper_limit>10.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For SPID 32-36.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>p-Value from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least-squares means</param_type>
            <param_value>3.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.13</ci_lower_limit>
            <ci_upper_limit>5.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For SPID 36-48.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.006</p_value>
            <p_value_desc>p-Value from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least-squares means</param_type>
            <param_value>6.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.82</ci_lower_limit>
            <ci_upper_limit>10.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For SPID 44-48.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.042</p_value>
            <p_value_desc>p-Value from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least-squares means</param_type>
            <param_value>2.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.09</ci_lower_limit>
            <ci_upper_limit>4.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For SPID 24-48.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>p-Value from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least-squares means</param_type>
            <param_value>10.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.49</ci_lower_limit>
            <ci_upper_limit>18.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Dose of Rescue Medication After First Dose of Study Drug</title>
        <description>During the first 12 hours of the study, participants not experiencing adequate relief after the 1-hour time point were allowed to take a single tablet (dose) of acetaminophen/hydrocodone hydrochloride (HCl) 500 mg/5 mg as a rescue medication (the only rescue medication allowed). The time at which rescue medication was taken was recorded.</description>
        <time_frame>Baseline to 12 hours</time_frame>
        <population>ITT population. Here, “Number of participants analysed signifies those participants who were evaluable for this outcome measures”.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo 1 matching caplet administered orally up to 5 hours after surgery, thereafter every 12 hours up to 48 hours</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen</title>
            <description>Ibuprofen 600 milligrams (mg) extended release (ER) caplet administered orally up to 5 hours after surgery, thereafter every 12 hours up to 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Dose of Rescue Medication After First Dose of Study Drug</title>
          <description>During the first 12 hours of the study, participants not experiencing adequate relief after the 1-hour time point were allowed to take a single tablet (dose) of acetaminophen/hydrocodone hydrochloride (HCl) 500 mg/5 mg as a rescue medication (the only rescue medication allowed). The time at which rescue medication was taken was recorded.</description>
          <population>ITT population. Here, “Number of participants analysed signifies those participants who were evaluable for this outcome measures”.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" lower_limit="1.4" upper_limit="2.2"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Median time was more than 12 hours. 95% CI was not estimable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>proportional hazards model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.10</ci_lower_limit>
            <ci_upper_limit>0.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Taking Rescue Medication</title>
        <description>Participants not experiencing adequate relief after the 1-hour time point during each dosing interval were allowed to take a single tablet (dose) of acetaminophen/hydrocodone HCl 500 mg/5 mg as a rescue medication (the only rescue medication allowed) during each interval.</description>
        <time_frame>Baseline to 48 hours</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo 1 matching caplet administered orally up to 5 hours after surgery, thereafter every 12 hours up to 48 hours</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen</title>
            <description>Ibuprofen 600 milligrams (mg) extended release (ER) caplet administered orally up to 5 hours after surgery, thereafter every 12 hours up to 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Taking Rescue Medication</title>
          <description>Participants not experiencing adequate relief after the 1-hour time point during each dosing interval were allowed to take a single tablet (dose) of acetaminophen/hydrocodone HCl 500 mg/5 mg as a rescue medication (the only rescue medication allowed) during each interval.</description>
          <population>ITT population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First dosing interval (0 to 12 hours)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9"/>
                    <measurement group_id="O2" value="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second dosing interval (12 to 24 hours)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.8"/>
                    <measurement group_id="O2" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Third dosing interval (24 to 36 hours)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.7"/>
                    <measurement group_id="O2" value="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fourth dosing interval (36 to 48 hours)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2"/>
                    <measurement group_id="O2" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall during the study (0 to 48 hours)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.8"/>
                    <measurement group_id="O2" value="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>During the first dosing interval (0 to 12 hours).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Values from the Cochran-Mantel-Haenszel (CMH) test, controlling for baseline PSR and gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Treatment Difference</param_type>
            <param_value>-48.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-64.46</ci_lower_limit>
            <ci_upper_limit>-31.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>During the second dosing interval (12 to 24 hours).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Values from the CMH test, controlling for baseline PSR and gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Treatment Difference</param_type>
            <param_value>-25.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-39.78</ci_lower_limit>
            <ci_upper_limit>-11.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>During the third dosing interval (24 to 36 hours).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>p-Values from the CMH test, controlling for baseline PSR and gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Treatment Difference</param_type>
            <param_value>-24.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-38.93</ci_lower_limit>
            <ci_upper_limit>-9.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>During the fourth dosing interval (36 to 48 hours).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.035</p_value>
            <p_value_desc>p-Values from the CMH test, controlling for baseline PSR and gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Treatment Difference</param_type>
            <param_value>-13.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-26.41</ci_lower_limit>
            <ci_upper_limit>-0.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>During the study overall (0 to 48 hours).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Values from the CMH test, controlling for baseline PSR and gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Treatment Difference</param_type>
            <param_value>-48.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-64.42</ci_lower_limit>
            <ci_upper_limit>-31.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Time to First Dose Rescue Medication Over Entire Study Period (0-48 Hours)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>Andersen-Gill (AG)</method>
            <param_type>Cox proportional hazard models</param_type>
            <param_value>0.086</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>0.57</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Relief (PR) Scores</title>
        <description>A 5-point categorical pain relief rating scale was used to rate pain relief in response to the question: &quot;How much relief do you have from your starting pain?&quot; Responses were scored as follows: 0=none, 1=a little, 2=some, 3=a lot, 4=complete. Higher score indicated more pain relief.</description>
        <time_frame>0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 hours</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo 1 matching caplet administered orally up to 5 hours after surgery, thereafter every 12 hours up to 48 hours</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen</title>
            <description>Ibuprofen 600 milligrams (mg) extended release (ER) caplet administered orally up to 5 hours after surgery, thereafter every 12 hours up to 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief (PR) Scores</title>
          <description>A 5-point categorical pain relief rating scale was used to rate pain relief in response to the question: &quot;How much relief do you have from your starting pain?&quot; Responses were scored as follows: 0=none, 1=a little, 2=some, 3=a lot, 4=complete. Higher score indicated more pain relief.</description>
          <population>ITT population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.7"/>
                    <measurement group_id="O2" value="1.3" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.0"/>
                    <measurement group_id="O2" value="2.2" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.0"/>
                    <measurement group_id="O2" value="2.6" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.0"/>
                    <measurement group_id="O2" value="2.8" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.3"/>
                    <measurement group_id="O2" value="2.9" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="1.3"/>
                    <measurement group_id="O2" value="2.8" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="1.3"/>
                    <measurement group_id="O2" value="2.4" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.3"/>
                    <measurement group_id="O2" value="2.1" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1.5"/>
                    <measurement group_id="O2" value="1.9" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 0.5 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.50</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 1 hour.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>1.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>1.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 1.5 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>2.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.56</ci_lower_limit>
            <ci_upper_limit>2.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 2 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>2.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.86</ci_lower_limit>
            <ci_upper_limit>2.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 4 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>2.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.69</ci_lower_limit>
            <ci_upper_limit>2.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 6 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>1.38</ci_upper_limit>
            <estimate_desc>Treatment difference (ibuprofen minus placebo) and corresponding 95% CI were calculated based on least-squares means from the ANOVA model.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 8 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>1.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 10 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.60</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 12 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.052</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.00</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Intensity Difference (PID) Scores</title>
        <description>For pain intensity, &quot;How much pain do you have at this time?&quot; answered on a 4-point categorical scale. Responses were scored as follows: 0=none, 1=mild, 2=moderate, 3=severe. PID score=baseline pain intensity score minus score at each time point. PID scores ranged from -1 to 3. Higher positive PID scores indicated greater improvement (decrease in pain intensity).</description>
        <time_frame>0.5, 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 hours</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo 1 matching caplet administered orally up to 5 hours after surgery, thereafter every 12 hours up to 48 hours</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen</title>
            <description>Ibuprofen 600 milligrams (mg) extended release (ER) caplet administered orally up to 5 hours after surgery, thereafter every 12 hours up to 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity Difference (PID) Scores</title>
          <description>For pain intensity, &quot;How much pain do you have at this time?&quot; answered on a 4-point categorical scale. Responses were scored as follows: 0=none, 1=mild, 2=moderate, 3=severe. PID score=baseline pain intensity score minus score at each time point. PID scores ranged from -1 to 3. Higher positive PID scores indicated greater improvement (decrease in pain intensity).</description>
          <population>ITT population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.6"/>
                    <measurement group_id="O2" value="0.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.8"/>
                    <measurement group_id="O2" value="1.0" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.9"/>
                    <measurement group_id="O2" value="1.2" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0" spread="0.8"/>
                    <measurement group_id="O2" value="1.4" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="1.0"/>
                    <measurement group_id="O2" value="1.4" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.0"/>
                    <measurement group_id="O2" value="1.3" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.9"/>
                    <measurement group_id="O2" value="1.0" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.9"/>
                    <measurement group_id="O2" value="0.9" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.2"/>
                    <measurement group_id="O2" value="0.8" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>16 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.9"/>
                    <measurement group_id="O2" value="1.6" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.0"/>
                    <measurement group_id="O2" value="1.4" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="1.0"/>
                    <measurement group_id="O2" value="1.2" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.1"/>
                    <measurement group_id="O2" value="1.6" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>32 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.0"/>
                    <measurement group_id="O2" value="1.6" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.0"/>
                    <measurement group_id="O2" value="1.0" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.0"/>
                    <measurement group_id="O2" value="1.6" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>44 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.0"/>
                    <measurement group_id="O2" value="1.6" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="1.0"/>
                    <measurement group_id="O2" value="1.6" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 0.5 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.16</ci_lower_limit>
            <ci_upper_limit>0.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 1 hour.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline pain severity, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 1.5 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline pain severity, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>1.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.91</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 2 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline pain severity, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>1.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.10</ci_lower_limit>
            <ci_upper_limit>1.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 4 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline pain severity, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>1.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>1.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 6 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline pain severity, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.30</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 8 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline pain severity, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>0.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.31</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 10 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline pain severity, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 12 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.089</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline pain severity, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.04</ci_lower_limit>
            <ci_upper_limit>0.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 16 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Ibuprofen versus placebo at 0.5 hours.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 20 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>0.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.15</ci_lower_limit>
            <ci_upper_limit>0.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 24 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.821</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>0.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 28 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>0.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.23</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 32 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.30</ci_lower_limit>
            <ci_upper_limit>0.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 36 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.127</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.07</ci_lower_limit>
            <ci_upper_limit>0.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 40 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.35</ci_lower_limit>
            <ci_upper_limit>1.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 44 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.036</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>0.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 48 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.091</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>0.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.04</ci_lower_limit>
            <ci_upper_limit>0.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Relief Combined With Pain Intensity (PRID) Scores</title>
        <description>PRID score=PR plus PID. 5-point categorical scale for PR: &quot;How much relief do you have from your starting pain?&quot; (0=none, 1=a little, 2=some, 3=a lot, 4=complete). 4-point categorical scale for pain intensity: &quot;How much pain do you have at this time?&quot; (0=none, 1=mild, 2=moderate, 3=severe). PID score=baseline pain intensity score minus pain intensity at each time point; PID score ranged from -1 to 3; higher positive PID value=improvement. PRID scores ranged from -1 to 7. Higher PRID scores indicated better pain relief and decrease in pain intensity.</description>
        <time_frame>0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 hours</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo 1 matching caplet administered orally up to 5 hours after surgery, thereafter every 12 hours up to 48 hours</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen</title>
            <description>Ibuprofen 600 milligrams (mg) extended release (ER) caplet administered orally up to 5 hours after surgery, thereafter every 12 hours up to 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Relief Combined With Pain Intensity (PRID) Scores</title>
          <description>PRID score=PR plus PID. 5-point categorical scale for PR: &quot;How much relief do you have from your starting pain?&quot; (0=none, 1=a little, 2=some, 3=a lot, 4=complete). 4-point categorical scale for pain intensity: &quot;How much pain do you have at this time?&quot; (0=none, 1=mild, 2=moderate, 3=severe). PID score=baseline pain intensity score minus pain intensity at each time point; PID score ranged from -1 to 3; higher positive PID value=improvement. PRID scores ranged from -1 to 7. Higher PRID scores indicated better pain relief and decrease in pain intensity.</description>
          <population>ITT population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.5 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.1"/>
                    <measurement group_id="O2" value="1.8" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.7"/>
                    <measurement group_id="O2" value="3.2" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1.5 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.7"/>
                    <measurement group_id="O2" value="3.8" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.7"/>
                    <measurement group_id="O2" value="4.1" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="2.2"/>
                    <measurement group_id="O2" value="4.3" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="2.2"/>
                    <measurement group_id="O2" value="4.0" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="2.1"/>
                    <measurement group_id="O2" value="3.5" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="2.0"/>
                    <measurement group_id="O2" value="3.0" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="2.6"/>
                    <measurement group_id="O2" value="2.7" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 0.5 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>1.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>1.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 1 hour.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>2.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.77</ci_lower_limit>
            <ci_upper_limit>3.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 1.5 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>3.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.49</ci_lower_limit>
            <ci_upper_limit>3.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 2 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>3.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.98</ci_lower_limit>
            <ci_upper_limit>4.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 4 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>3.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.67</ci_lower_limit>
            <ci_upper_limit>4.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 6 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>1.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>2.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 8 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>1.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>2.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 10 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>1.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.97</ci_lower_limit>
            <ci_upper_limit>2.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 12 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.056</p_value>
            <p_value_desc>p-Values from ANOVA model with treatment, baseline PSR, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.02</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-weighted Sum of Pain Relief Scores (TOTPAR)</title>
        <description>TOTPAR is a derived endpoint from PR scores. 5-point categorical scale for PR: &quot;How much relief do you have from your starting pain?&quot; (0=none, 1=a little, 2=some, 3=a lot, 4=complete). TOTPAR 0-12 scores ranged from 0 (worst) to 48 (best). TOTPAR 8-12 scores ranged from 0 (worst) to 16 (best).</description>
        <time_frame>0-12 hours, 8-12 hours</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo 1 matching caplet administered orally up to 5 hours after surgery, thereafter every 12 hours up to 48 hours</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen</title>
            <description>Ibuprofen 600 milligrams (mg) extended release (ER) caplet administered orally up to 5 hours after surgery, thereafter every 12 hours up to 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Time-weighted Sum of Pain Relief Scores (TOTPAR)</title>
          <description>TOTPAR is a derived endpoint from PR scores. 5-point categorical scale for PR: &quot;How much relief do you have from your starting pain?&quot; (0=none, 1=a little, 2=some, 3=a lot, 4=complete). TOTPAR 0-12 scores ranged from 0 (worst) to 48 (best). TOTPAR 8-12 scores ranged from 0 (worst) to 16 (best).</description>
          <population>ITT population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TOTPAR 0 to 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" spread="11.2"/>
                    <measurement group_id="O2" value="28.7" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TOTPAR 8 to 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="7.2"/>
                    <measurement group_id="O2" value="12.9" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 0 to 12 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Value from ANOVA model with treatment, baseline pain severity, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>14.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.38</ci_lower_limit>
            <ci_upper_limit>19.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo from 8 to 12 hours.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Value from ANOVA model with treatment, baseline pain severity, and gender terms.</p_value_desc>
            <method>ANOVA</method>
            <param_type>Least squares means</param_type>
            <param_value>5.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.57</ci_lower_limit>
            <ci_upper_limit>7.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Doses of Rescue Medication Used</title>
        <time_frame>0-12, 12-24, 24-36, 36-48, 0-48 hours</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo 1 matching caplet administered orally up to 5 hours after surgery, thereafter every 12 hours up to 48 hours</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen</title>
            <description>Ibuprofen 600 milligrams (mg) extended release (ER) caplet administered orally up to 5 hours after surgery, thereafter every 12 hours up to 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Doses of Rescue Medication Used</title>
          <population>ITT population</population>
          <units>doses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First dosing interval (0-12 hours)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.0"/>
                    <measurement group_id="O2" value="0.4" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second dosing interval (12-24 hours)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.6"/>
                    <measurement group_id="O2" value="0.1" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Third dosing interval (24-36 hours)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.9"/>
                    <measurement group_id="O2" value="0.1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fourth dosing interval (36-48 hours)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.7"/>
                    <measurement group_id="O2" value="0.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Overall during the study (0-48 hours)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="2.6"/>
                    <measurement group_id="O2" value="0.6" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the first dosing interval.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Values from the CMH test with modified ridit scores, controlling for baseline PSR and gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>CMH-adjusted proportion</param_type>
            <param_value>-0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.91</ci_lower_limit>
            <ci_upper_limit>-0.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the second dosing interval.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment difference (ibuprofen minus placebo) and corresponding 95% CI were calculated based on CMH-adjusted proportions and corresponding standard errors.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>CMH-adjusted proportions</param_type>
            <param_value>-0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.05</ci_lower_limit>
            <ci_upper_limit>-0.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the third dosing interval.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>p-Values from the CMH test with modified ridit scores, controlling for baseline PSR and gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>CMH-adjusted proportions</param_type>
            <param_value>-0.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.90</ci_lower_limit>
            <ci_upper_limit>-0.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>For the fourth dosing interval.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.021</p_value>
            <p_value_desc>p-Values from the CMH test with modified ridit scores, controlling for baseline PSR and gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>CMH-adjusted proportion</param_type>
            <param_value>-0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.02</ci_lower_limit>
            <ci_upper_limit>-0.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the overall study duration.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Values from the CMH test with modified ridit scores, controlling for baseline PSR and gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>CMH-adjusted proportion</param_type>
            <param_value>-0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.89</ci_lower_limit>
            <ci_upper_limit>-0.51</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Confirmed First Perceptible Relief</title>
        <description>The elapsed time from dosing until the participant indicated first perceptible pain relief by pressing the first stopwatch, provided the participant also indicated achieving meaningful relief by pressing the second stopwatch. Perceptible relief defined as when participant first began to feel any pain-relieving effect whatsoever of the drug. Did not necessarily mean the participant felt completely better, but when the participant first felt any difference in the pain he/she is currently feeling.</description>
        <time_frame>Baseline to 12 hours</time_frame>
        <population>ITT population. Here, “Number of participants analysed signifies those participants who were evaluable for this outcome measures”.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo 1 matching caplet administered orally up to 5 hours after surgery, thereafter every 12 hours up to 48 hours</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen</title>
            <description>Ibuprofen 600 milligrams (mg) extended release (ER) caplet administered orally up to 5 hours after surgery, thereafter every 12 hours up to 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Confirmed First Perceptible Relief</title>
          <description>The elapsed time from dosing until the participant indicated first perceptible pain relief by pressing the first stopwatch, provided the participant also indicated achieving meaningful relief by pressing the second stopwatch. Perceptible relief defined as when participant first began to feel any pain-relieving effect whatsoever of the drug. Did not necessarily mean the participant felt completely better, but when the participant first felt any difference in the pain he/she is currently feeling.</description>
          <population>ITT population. Here, “Number of participants analysed signifies those participants who were evaluable for this outcome measures”.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Median time to first perceptible relief was more than 720 minutes. 95% CI was not estimable.</measurement>
                    <measurement group_id="O2" value="25.0" lower_limit="20.1" upper_limit="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Meaningful Relief</title>
        <description>Participants evaluated the time to meaningful relief by depressing a second stopwatch at the moment they first began to experience meaningful relief, defined as relief from the pain that was considered meaningful to the participant.</description>
        <time_frame>Baseline to 12 hours</time_frame>
        <population>ITT population. Here, “Number of participants analysed signifies those participants who were evaluable for this outcome measures”.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo 1 matching caplet administered orally up to 5 hours after surgery, thereafter every 12 hours up to 48 hours</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen</title>
            <description>Ibuprofen 600 milligrams (mg) extended release (ER) caplet administered orally up to 5 hours after surgery, thereafter every 12 hours up to 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Meaningful Relief</title>
          <description>Participants evaluated the time to meaningful relief by depressing a second stopwatch at the moment they first began to experience meaningful relief, defined as relief from the pain that was considered meaningful to the participant.</description>
          <population>ITT population. Here, “Number of participants analysed signifies those participants who were evaluable for this outcome measures”.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Time to meaningful relief was more than 720 minutes. 95% CI not calculated.</measurement>
                    <measurement group_id="O2" value="54.2" lower_limit="46.5" upper_limit="79.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Global Evaluation Score</title>
        <description>Participants responded, on a 6-point categorical scale, to the following question: &quot;How would you rate this medication as a pain-reliever?&quot; Responses on this categorical scale ranged as follows: 0=very poor, 1=poor, 2=fair, 3=good, 4=very good, 5=excellent.</description>
        <time_frame>24 and 48 hours</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo 1 matching caplet administered orally up to 5 hours after surgery, thereafter every 12 hours up to 48 hours</description>
          </group>
          <group group_id="O2">
            <title>Ibuprofen</title>
            <description>Ibuprofen 600 milligrams (mg) extended release (ER) caplet administered orally up to 5 hours after surgery, thereafter every 12 hours up to 48 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Global Evaluation Score</title>
          <description>Participants responded, on a 6-point categorical scale, to the following question: &quot;How would you rate this medication as a pain-reliever?&quot; Responses on this categorical scale ranged as follows: 0=very poor, 1=poor, 2=fair, 3=good, 4=very good, 5=excellent.</description>
          <population>ITT population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="1.4"/>
                    <measurement group_id="O2" value="3.5" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="1.5"/>
                    <measurement group_id="O2" value="3.7" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 24 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>p-Value from the CMH test with modified ridit scores, controlling for baseline PSR score and gender.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Gamma statistic</param_type>
            <param_value>0.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Ibuprofen versus placebo at 48 hours</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>p-Value from the CMH test with modified ridit scores, controlling for baseline PSR score and gender.</method_desc>
            <param_type>Gamma statistic</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo 1 matching caplet administered orally up to 5 hours after surgery, thereafter every 12 hours up to 48 hours</description>
        </group>
        <group group_id="E2">
          <title>Ibuprofen</title>
          <description>Ibuprofen 600 milligrams (mg) extended release (ER) caplet administered orally up to 5 hours after surgery, thereafter every 12 hours up to 48 hours</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

